Please use this identifier to cite or link to this item:
Groot, Carin A. Uyl-de
van Rooijen, Elisabeth M.
Punt, Cornelis J. A.
Pescott, Chris P.
Year of Publication: 
[Journal:] Health Economics Review [ISSN:] 2191-1991 [Volume:] 8 [Issue:] 13 [Publisher:] Springer [Place:] Heidelberg [Year:] 2018 [Pages:] 1-8
Springer, Heidelberg
Objective: To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC). Methods: Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC in eight hospitals in the Netherlands between 2009 and 2012 were included in our real-world study. Outcome measures were costs per life-year (LY) and costs per quality-adjusted LY (QALY) gained. A Markov model was developed, and a time horizon of four years was applied. Outcomes were calculated from Kaplan-Meier survival curves from patient-level data and literature. Direct medical costs were estimated in all centers (2013 values), and incremental cost-effectiveness ratios (ICERs) were calculated. Results were discounted, and a probabilistic sensitivity analysis was performed. Results: Administration of cetuximab in third-line treatment of mCRC resulted in a gain of 0.29 LYs and 0.25 QALYs compared with BSC. In the four-year study period, average discounted healthcare costs were €36,637 in the cetuximab group vs. €3648 in the BSC group. The discounted ICERs of cetuximab vs. BSC in the real-world setting were €114,907and €133,527 per LY and QALY gained, respectively. Conclusions: Results of this cost-effectiveness analysis showed that third-line treatment with cetuximab for patients with KRAS (exon 2) wt mCRC offered clinical benefits at additional cost. The real-world ICERs were in line with those of previously published cetuximab and panitumumab cost-utility models.
Cost effectiveness
Metastatic colorectal cancer
Third-line treatment
Persistent Identifier of the first edition: 
Creative Commons License: 
cc-by Logo
Document Type: 

Files in This Item:
827.73 kB

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.